Phase II trial for PD-1 Antibody (SHR-1210) and the CDK4/6 Inhibitor SHR6390 in the treatment of Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Latest Information Update: 05 Jul 2019
At a glance
- Drugs Camrelizumab (Primary) ; Dalpiciclib (Primary)
- Indications B-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 05 Jul 2019 New trial record